Dr Simon Crabb
University of Southampton
Dr Simon Crabb is an Associate Professor in Medical Oncology at the University of Southampton and an Honorary Consultant specialising in genitourinary cancers at University Hospital Southampton in the United Kingdom. His research interests are focussed on the development of novel therapeutic strategies for prostate and bladder cancers. Dr Crabb is Associate Clinical Director of the Southampton Clinical Trials Unit, Deputy Director of the Southampton Experimental Cancer Medicine Centre and a lead for phase I cancer clinical trials. He has been a member of NCRI Clinical Studies Groups for prostate cancer, and bladder and renal cancer and the Experimental Medicine Expert Review Panel for Cancer Research UK. Dr Crabb is an active clinical trialist including as Chief Investigator on the CRUK funded ProCAID and POLERISE trials in prostate cancer.
Novel Therapeutic Strategies for Advanced Prostate Cancer
Prostate cancer continues to kill over 10,000 patients annually in the UK. Survival outcomes have extended in recent years through introduction of novel treatment strategies but in general, these have been modest gains. Rapid development in our understanding of disease biology, clonal evolution and intra-tumour heterogeneity are providing promise that we can develop more rationally targeted therapeutic strategies. This seminar will explore current examples of these approaches in clinical development.
EVEN MORE SEMINARS
Dr Christy Goldsmith Action Radiotherapy
Improving patient outcomes with Stereotactic Ablative Body Radiotherapy (SABR)
Dr Ioanna Nixon Beatson West of Scotland Cancer center, NHS Greater Glasgow and Clyde
When the oncologist meets the patient: value of compassion. How well are we doing?
Emlyn Samuel Cancer Research UK
Brexit: getting the best outcome for research and patients
Nirmesh Patel Cambridge Cancer Genomics
Monitoring cancer evolution through smart genomics and liquid biopsies
Philip Beer MRCP, FRCPath, PhD ONCODNA S.A
The evolution of oncology therapeutics in the genomic era.